Real-time regulatory updates from DEA, DOJ, FDA, CMS, and all 50 state medical boards — curated and analyzed by AI, reviewed by compliance experts. Built to help you stay ahead of healthcare regulation changes.
All 50 States + DC
350+ Regulatory Topics
Regulatory Intelligence Feed
0 articles published
Guides & Templates
In-Depth Compliance Resources
Comprehensive guides, checklists, and templates to help you navigate healthcare compliance — from CPOM structuring to GFE requirements and medical director agreements.
Our AI-powered intelligence engine monitors DEA, DOJ, FDA, CMS, and all 50 state medical boards so you never miss a compliance update that affects your business.
The Drug Enforcement Administration (DEA) has issued a proposed rule to transfer three substances—suvorexant, lemborexant, and daridorexant—from Schedule IV to Schedule V of the Controlled Substances Act (CSA). If finalized, this action would impose the regulatory controls and sanctions applicable to Schedule V substances on all individuals and entities handling these medications. Interested parties have until September 10, 2026, to submit comments or request a hearing.
The Department of Justice (DOJ) and the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) announced a major national health care fraud takedown on June 23, 2026. This enforcement action charged 455 defendants in schemes totaling over $6.5 billion, with a significant portion, involving 49 defendants and $1.17 billion, specifically targeting telemedicine and genetic testing fraud. Providers should note the strong emphasis on data-driven enforcement and Medicaid fraud.
The U.S. Drug Enforcement Administration (DEA) has yet to finalize its permanent rules for prescribing controlled substances via telemedicine, despite extending temporary flexibilities. In Virginia, practitioners must continue to adhere to the existing framework outlined in the Virginia Drug Control Act, which provides critical definitions for drug handling and administration within the Commonwealth.
The Maine Department of Health and Human Services (DHHS) has issued a reminder emphasizing that all providers delivering telehealth services to MaineCare members must hold appropriate Maine licensure or utilize recognized interstate compacts. Non-compliance with these licensure requirements, as outlined in the MaineCare Benefits Manual (MBM), Chapter I, Section 4, will result in the denial of claims or recoupment of payments.
The Kentucky Board of Medical Licensure (KBML) upholds the Kentucky Medical Practice Act (KRS 311.530 to 311.620), which governs the practice of medicine and osteopathy within the Commonwealth. This extensive framework outlines essential requirements for licensure, defines professional conduct, and addresses specific duties for physicians employing telehealth in patient care.
A Texas physician, Maryam Qayum, M.D., was sentenced to 12.5 years in prison for operating an illegal pill mill that unlawfully distributed over 3 million opioid pills. Her Kingwood clinic, Recare Health Clinic, operated as a cash-only enterprise, issuing prescriptions for highly addictive opioids without legitimate medical purpose or patient interaction.
Victory Medical Center Pharmacy has voluntarily recalled specific lots of Compounded Glutathione 200 mg/mL Multi-Dose Vials nationwide due to the detection of elevated bacterial endotoxin levels. The injectable product, distributed to consumers in Texas, Florida, and New York, carries a risk of serious medical events including anaphylactic shock and death.
On June 23, 2026, the Department of Justice announced a national health care fraud takedown, charging a record 455 defendants, including 90 medical professionals, for schemes involving over $6.5 billion in alleged false claims. The enforcement effort demonstrates a heightened focus on telemedicine and genetic testing schemes, as well as significant coordination targeting Medicaid fraud through data-driven strategies.
The Federation of State Medical Boards (FSMB) asserts that while artificial intelligence (AI) is a powerful tool in medicine, it should not be independently licensed. The FSMB guidance emphasizes that professional responsibility and accountability for patient care, even when AI is utilized, remains with the licensed human clinician.
The FDA has announced significant class-wide labeling changes for all approved testosterone products. These updates incorporate findings from the TRAVERSE clinical trial, removing the Boxed Warning related to increased cardiovascular risk, and add new warnings regarding increased blood pressure based on postmarket studies.
The Drug Enforcement Administration (DEA) has issued a Notice of Proposed Rulemaking to modify the listing of 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid), a List I chemical under the Controlled Substances Act (CSA). The proposed amendment seeks to include esters of this chemical, along with its salts, optical and geometric isomers, and salts of isomers, within its classification as a List I chemical. This action aims to broaden the scope of control over this precursor chemical, which is crucial for manufacturing controlled substances.
The Federal Trade Commission, alongside regulators from Utah and California, has filed a lawsuit against telehealth provider Hims & Hers. The lawsuit alleges the company engaged in deceptive practices, specifically by sharing consumers' sensitive health information with third-party advertisers and by implementing deceptive billing and challenging subscription cancellation processes.
Massachusetts House Bill H.2393, aimed at authorizing the state's entry into the Interstate Medical Licensure Compact (IMLC), has moved forward in the legislative process. The bill was favorably reported by the Public Health committee and subsequently referred to the House Committee on Ways and Means, indicating progress toward facilitating multi-state licensure for physicians.
The Federal Trade Commission (FTC) has initiated its first enforcement action under the Health Breach Notification Rule against GoodRx, alleging the company illegally shared consumers' sensitive health information with advertising platforms like Facebook and Google. GoodRx faces a $1.5 million civil penalty and a prohibition on sharing user health data for advertising purposes under a proposed order. This action underscores the FTC's commitment to protecting health data privacy, especially from digital health platforms.
CMS has finalized a new, simplified 3-step process for adding services to the Medicare Telehealth Services List, making all services identified for 2026 permanent. This update also removes certain frequency limits, permits direct supervision for specific diagnostic imaging via telehealth, and incorporates new behavioral and infectious disease services.
